Stay updated with breaking news from கோர் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Midway through trading Monday, the Dow traded up 2.09% to 31,580.33 while the NASDAQ rose 2.56% to 13,530.07. The S&P also rose, gaining 2.28% to . ....
Message : Required fields ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Australia, supplying therapy to patients suffering with primary headache disorders. The announcement follows the granting of regulatory approval from the Australian Therapeutic Goods Administration (TGA) for the promotion and sale of the gammaCore Sapphire family of products. “We are delighted to welcome Jeneth Boughen, Owner and General Manager of Medistar, and the team at Medistar into our growing network of select distribution partners,” said Iain Strickland, electroCore’s Vice President of European Operations. “Medistar has demonstrable expertise in medical device distr ....
electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
2 “gammaCore (nVNS) is the only treatment option, drug or device, that is currently available for the acute and preventive treatment of migraine in adolescents,” said Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “With their interest in technology and desire to avoid prescription drugs, gammaCore represents a unique treatment for adolescents with migraine. We would like to thank the Division of Neuromodulation and Physical Medicine Devices and their colleagues at the FDA for their efforts to review and clear the expanded label for gammaCore. The label expansion was based on previously reported randomized controlled trials of gammaCore for the acute and preventive treatment of migraine, and was supported by a small study (n=9) in adolescents where 46.8% of all treated attacks were successfully resolved without the use of any acute rescue medication. ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to . electroCoreFebruary 9, 2021 GMT ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal Colorectal Disease. The paper reports on the results of a parallel group, randomized controlled trial conducted at St. James’s University Hospital in Leeds, England. The study was funded by the Bowel Research UK supported by the National Institute for Health Research (NIHR) Surgical MedTech Co-operative. ....